5AM Venture Management
SAN FRANCISCO, CAfiles as 5AM Venture Management, LLC
$288m in 16 US stocks at the end of 30 June 2026. The top 10 are 85.6% of the money. It changed about 29.7% of the portfolio this quarter.
Value
$288m
Stocks
16
Top 10 share
85.6%
Turnover
29.7%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- SurrozenSRZN2.4% of the fund-30%
Sold out
Sold their entire stake.
- ErascaERAS-100%
- Centessa Pharmaceuticals-100%
- GH ResearchGHRS-100%
- RallybioRLYB-100%
Holdings
- Skye Bioscience
- Share
- 2.3%
- Value
- $7m
- Shares
- 9,681,763
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| MapLight TherapeuticsMPLT | 11.8% | $34m | 950,011 | Held |
| Tyra BiosciencesTYRA | 11.4% | $33m | 1,029,298 | Held |
| Entrada TherapeuticsTRDA | 10.4% | $30m | 4,056,379 | Held |
| PharvarisPHVS | 9.6% | $28m | 797,600 | Held |
| Camp4 TherapeuticsCAMP | 8.9% | $26m | 5,869,091 | Held |
| Artiva BiotherapeuticsARTV | 7.9% | $23m | 2,353,304 | Held |
| Tectonic TherapeuticTECX | 7.2% | $21m | 606,660 | Held |
| Zentalis PharmaceuticalsZNTL | 6.7% | $19m | 3,947,913 | Held |
| Celldex TherapeuticsCLDX | 6.4% | $19m | 497,270 | Held |
| EyePointEYPT | 5.2% | $15m | 1,050,000 | Held |
| BiohavenBHVN | 3.8% | $11m | 738,972 | Held |
| SurrozenSRZN | 2.4% | $7m | 271,250 | -30% |
| Skye Bioscience | 2.3% | $7m | 9,681,763 | Held |
| ALX Oncology HoldingsALXO | 2.2% | $6m | 3,057,325 | Held |
| Protara TherapeuticsTARA | 1.8% | $5m | 1,369,782 | Held |
| Silence TherapeuticsSLN | 1.8% | $5m | 476,200 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 10.7% since 30 June 2025.
Where the money is
Health care97.7%
Other2.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.